Marketing
-
Sponsored by Veeva
Give HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
BIO changes stance, backs bill to limit China’s role in US biotech
Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.
By Jonathan Gardner • March 14, 2024 -
Trendline
Pharma, new drugs and market strategy
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
ALS drug development
After surprise trial failure, ALS doctors brace for one less treatment option
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
By Jacob Bell • March 12, 2024 -
Novavax agrees to pay Gavi in settlement over COVID vaccine contract
Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.
By Kristin Jensen • Feb. 22, 2024 -
Ipsen drug approved by FDA for early pancreatic cancer
The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.
By Ned Pagliarulo • Feb. 14, 2024 -
New Alzheimer's drugs
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.
By Jacob Bell • Feb. 13, 2024 -
Sponsored by Alexander Group
Chart a course for sustainable growth
Explore how companies are optimizing efficiency, enhancing customer experiences and embracing AI.
Feb. 12, 2024 -
New Alzheimer's drugs
Eisai falls behind on Leqembi patient goal
The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.
By Jacob Bell • Feb. 6, 2024 -
Biogen quits Aduhelm, handing back rights to original developer
The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.
By Jacob Bell • Jan. 31, 2024 -
FDA orders new cancer warnings for CAR-T therapies
The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.
By Jonathan Gardner • Updated Jan. 24, 2024 -
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.
By Jacob Bell • Jan. 8, 2024 -
Lilly launches online service for home delivery of weight loss drug
The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.
By Ned Pagliarulo • Jan. 4, 2024 -
Sponsored by Alexander Group
Profitable growth is on the horizon
A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.
Dec. 11, 2023 -
CVS overhauls how its retail pharmacies charge for prescription drugs
Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.
By Rebecca Pifer • Dec. 5, 2023 -
Obesity drugs
European regulators want to know more about the risks of GLP-1 drugs
The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.
By Jacob Bell • Dec. 1, 2023 -
Cigna, Humana in talks to merge: WSJ
The merger would have major effects for the makeup of the U.S. health insurance industry, and would almost certainly face a regulatory challenge.
By Rebecca Pifer • Nov. 29, 2023 -
Medtronic CEO downplays impact of obesity drugs on procedures, devices
Surging demand for GLP-1 agonists has put medtech firms like Medtronic under pressure, even as they argue the hit to their businesses will be minimal.
By Ricky Zipp • Nov. 21, 2023 -
Bristol Myers faces FDA delay on cancer cell therapy decision
The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.
By Ned Pagliarulo • Nov. 20, 2023 -
New AMA policies target GLP-1 coverage, corporate medicine
The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.
By Susanna Vogel • Nov. 14, 2023 -
Obesity drugs
Wegovy study details revive debate over GLP-1 impact on devices
Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.
By Susan Kelly • Nov. 13, 2023 -
Biogen, Sage set price of postpartum depression pill at $15,900
The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.
By Ned Pagliarulo • Nov. 7, 2023 -
Sponsored by Viatris
Transforming MS care to meet patient needs
Developing holistic treatment approaches that address patient needs today and in the future.
By Abhijit Barve, MD, PhD, MBA, Chief Medical Officer, Viatris • Nov. 6, 2023 -
Obesity drugs
Novo, Lilly buoyed by fast-growing GLP-1 drug sales
The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.
By Jonathan Gardner • Nov. 2, 2023 -
Obesity drugs
The obesity drug effect: What medical device executives are saying
Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales.
By Susan Kelly • Nov. 2, 2023 -
RSV vaccines
GSK outpaces Pfizer in RSV vaccine market
Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.
By Kristin Jensen • Nov. 1, 2023